When is prostate cancer really cancer?

Urologic Clinics of North America

Volumn 41, Issue 2, 2014, Pages 339-346

  Berman, David M ^a   Epstein, Jonathan I ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Gleason grade; Low grade cancer; Prostate cancer; PSA screening

Indexed keywords

BASEMENT MEMBRANE; BENIGN TUMOR; CANCER CLASSIFICATION; CANCER GRADING; CANCER MORPHOLOGY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DOCTOR PATIENT RELATION; GLEASON SCORE; HUMAN; INTRADUCTAL CARCINOMA OF THE PROSTATE; LOW RISK POPULATION; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; RISK ASSESSMENT; TUMOR INVASION;

GLEASON GRADE; LOW-GRADE CANCER; PROSTATE CANCER; PSA SCREENING;

DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM GRADING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84898408388     PISSN: 00940143     EISSN: 1558318X     Source Type: Journal    
DOI: 10.1016/j.ucl.2014.01.006     Document Type: Review

References (48)

1. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
3. Egevad L. Recent trends in Gleason grading of prostate cancer: I. Pattern interpretation. Anal Quant Cytol Histol 2008, 30(4):190-198.
4. Hedrick L., Epstein J.I. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989, 13:389-396.
5. Totten R.S., Heinemann M.W., Hudson P.B., et al. Microscopic differential diagnosis of latent carcinoma of prostate. AMA Arch Pathol 1953, 55:131-141.
6. Evans A.J. Alpha-methylacyl CoA racemase (P504S): overview and potential uses in diagnostic pathology as applied to prostate needle biopsies. J Clin Pathol 2003, 56:892-897.
7. Häggarth L., Hägglöf C., Jaraj S.J., et al. Diagnostic biomarkers of prostate cancer. Scand J Urol Nephrol 2011, 45:60-67.
8. Wu C.L., Yang X.J., Tretiakova M., et al. Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia. Hum Pathol 2004, 35:1008-1013.
9. Häggman M.J., Wojno K.J., Pearsall C.P., et al. Allelic loss of 8p sequences in prostatic intraepithelial neoplasia and carcinoma. Urology 1997, 50:643-647.
10. Prasad M.A., Trybus T.M., Wojno K.J., et al. Homozygous and frequent deletion of proximal 8p sequences in human prostate cancers: identification of a potential tumor suppressor gene site. Genes Chromosomes Cancer 1998, 23:255-262.
11. Bismar T.A., Yoshimoto M., Vollmer R.T., et al. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer. BJU Int 2011, 107:477-485.
12. Mosquera J.M., Perner S., Genega E.M., et al. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008, 14:3380-3385.
13. Cooper G.M. Elements of human cancer 1992, Jones and Bartlett Publishers, Boston.
14. Robbins S.L., Kumar V. Robbins and Cotran pathologic basis of disease 2010, Saunders/Elsevier, Philadelphia.
15. Lazebnik Y. What are the hallmarks of cancer?. Nat Rev Cancer 2010, 10:232-233.
16. Tran B., Rosenthal M.A. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010, 17:417-421.
17. Chinem V.P., Miot H.A. Epidemiology of basal cell carcinoma. An Bras Dermatol 2011, 86:292-305.
18. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:230-234.
19. Salagierski M., Schalken J.A. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 2012, 187:795-801.
20. Robinson B.D., Epstein J.I. Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol 2010, 184:1328-1333.
21. Ahmed H.U., Arya M., Freeman A., et al. Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?. Lancet Oncol 2012, 13:e509-e517.
22. Lavery H.J., Droller M.J. Do Gleason patterns 3 and 4 prostate cancer represent separate disease states?. J Urol 2012, 188:1667-1675.
23. Bostwick D.G., Leske D.A., Qian J., et al. Prostatic intraepithelial neoplasia and well differentiated adenocarcinoma maintain an intact basement membrane. Pathol Res Pract 1995, 191:850-855.
24. Fuchs M.E., Brawer M.K., Rennels M.A., et al. The relationship of basement membrane to histologic grade of human prostatic carcinoma. Mod Pathol 1989, 2:105-111.
25. Carvalho F.L., Simons B.W., Antonarakis E.S., et al. Tumorigenic potential of circulating prostate tumor cells. Oncotarget 2013, 4:413-421.
26. Priolo C., Agostini M., Vena N., et al. Establishment and genomic characterization of mouse xenografts of human primary prostate tumors. Am J Pathol 2010, 176:1901-1913.
27. Bonkhoff H., Wernert N., Dhom G., et al. Distribution of basement membranes in primary and metastatic carcinomas of the prostate. Hum Pathol 1992, 23:934-939.
28. Pföhler C., Fixemer T., Jung V., et al. In situ hybridization analysis of genes coding collagen IV alpha1 chain, laminin beta1 chain, and S-laminin in prostate tissue and prostate cancer: increased basement membrane gene expression in high-grade and metastatic lesions. Prostate 1998, 36:143-150.
29. Liu W., Laitinen S., Khan S., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15:559-565.
30. Mehra R., Tomlins S.A., Yu J., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008, 68:3584-3590.
31. Sowalsky A.G., Ye H., Bubley G.J., et al. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res 2012, 73:1050-1055.
32. Cheng L., Slezak J., Bergstralh E.J., et al. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer 1999, 86:657-663.
33. Merrill M.M., Lane B.R., Reuther A.M., et al. Tumor volume does not predict for biochemical recurrence after radical prostatectomy in patients with surgical Gleason score 6 or less prostate cancer. Urology 2007, 70:294-298.
34. Epstein J.I., Carmichael M.J., Partin A.W., et al. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol 1994, 151:1587-1592.
35. Berney D.M. Low Gleason score prostatic adenocarcinomas are no longer viable entities. Histopathology 2007, 50:683-690.
36. Ross H.M., Kryvenko O.N., Cowan J.E., et al. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?. Am J Surg Pathol 2012, 36:1346-1352.
37. Eggener S.E., Scardino P.T., Walsh P.C., et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011, 185:869-875.
38. Carter H.B., Partin A.W., Walsh P.C., et al. Gleason score 6 adenocarcinoma: should it be labeled as cancer?. J Clin Oncol 2012, 30:4294-4296.
39. Nickel J.C., Speakman M. Should we really consider Gleason 6 prostate cancer?. BJU Int 2012, 109:645-646.
40. Pierorazio P.M., Walsh P.C., Partin A.W., et al. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int 2013, 111:753-760.
41. Moyer V.A. Screening for prostate cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2012, 157:120-134.
42. Wilt T.J., Brawer M.K., Jones K.M., et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012, 367:203-213.
43. Cooperberg M.R., Broering J.M., Carroll P.R. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010, 28:1117-1123.
44. Esserman L.J., Thompson I.M., Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA 2013, 310:797-798.
45. Robey R.B. Changing the terminology of cancer. JAMA 2014, 311:202-203.
46. Epstein J.I., Feng Z., Trock B.J., et al. Upgrading and downgradingofprostatecancer frombiopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading systemand factoring in tertiary grades. Eur Urol 2012, 61:1019-1024.
47. Davies J.D., Aghazadeh M.A., Phillips S., et al. Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol 2011, 186:2221-2227.
48. Kvåle R., Møller B., Wahlqvist R., et al. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 2009, 103:1647-1654.